Hyssop

What Is Hyssop?

Hyssop is a small, aromatic, semi-woody perennial of the mint family, native to southern Europe and the Mediterranean and long cultivated in herb and monastery gardens. It bears narrow leaves and spikes of blue-violet flowers, and has a warm, slightly bitter, camphoraceous scent. True hyssop is Hyssopus officinalis; it should not be confused with “anise hyssop” or “giant hyssop” (Agastache species), an unrelated North-American mint sold under a similar common name and with a very different chemistry.

Traditional & Modern Uses

Hyssop has a long history in European herbalism as an expectorant and respiratory remedy for coughs, colds and bronchial congestion, as a carminative for digestion, and as a diaphoretic to promote sweating in fevers. It is also used as a culinary herb and a flavouring in liqueurs. The plant is mentioned in many old herbals and has minor ceremonial and ritual-cleansing associations.

Phytochemistry

Hyssop’s essential oil is defined by its monoterpene ketone markers pinocamphone and isopinocamphone — the neurotoxic constituents — alongside 1,8-cineole, beta-pinene and limonene; some chemotypes also carry substantial methyleugenol, a compound of regulatory concern (see Safety) ^{6Reference 6Mićović T et al. · 2021In vitroAntioxidant, Antigenotoxic and Cytotoxic Activity of Essential Oils and Methanol Extracts of Hyssopus officinalis L. subsp. aristatus (Godr.) Nyman (Lamiaceae) — [in vitro]View study →}. The herb also supplies the diterpene lactone marrubiin, the phenolic acids rosmarinic, chlorogenic and caffeic, tannins, and flavonoids led by diosmin, luteolin and apigenin glycosides. The phenolic fraction carries most of the measured antioxidant and anti-inflammatory activity, though characterised extracts rate that antioxidant capacity only moderate-to-weak ^{6Reference 6Mićović T et al. · 2021In vitroAntioxidant, Antigenotoxic and Cytotoxic Activity of Essential Oils and Methanol Extracts of Hyssopus officinalis L. subsp. aristatus (Godr.) Nyman (Lamiaceae) — [in vitro]View study →}.

The single most important fact about hyssop’s chemistry is that it is strongly chemotype-dependent: the convulsant ketones pinocamphone and isopinocamphone dominate some populations and are nearly absent in others ^{27Reference 27Nurzyńska-Wierdak R · 2026ReviewOntogenetic and Environmental Variability of Hyssop (Hyssopus officinalis L.) Essential Oil Composition and Activity — [review]View study →}. “Hyssop oil” therefore cannot be treated as one substance, and a result tied to one oil batch transfers poorly to the dried herb or tea.

Constituent Summary

The essential-oil figures below are given as the approximate share of the oil and vary strongly by chemotype and origin — some French populations contain little or no pinocamphone at all. Diosmin is reported per dry shoot weight; rosmarinic acid is the dominant phenolic acid. † marks pinocamphone and isopinocamphone, the marker ketones whose presence and ratio differentiate hyssop chemotypes.

Pharmacology & Research

The research base for hyssop (Hyssopus officinalis) is modest and heavily preclinical. Most of the ~90 indexed papers characterise the essential oil’s chemistry or test crude extracts in cell lines and rodent models; a single small human trial exists — a 2024 randomised placebo-controlled study of hyssop syrup in asthma ^{1Reference 1Daneshfard B et al. · 2024RCTEffect of Hyssop (Hyssopus officinalis) Syrup on Mild to Moderate Asthma — [randomised double-blind placebo-controlled trial]View study →}. The most interesting emerging signals are the herb’s α-glucosidase-inhibiting (antidiabetic) fraction, its COX-2-mediated anti-inflammatory activity, and two historic in vitro reports of anti-HIV activity. A structural caveat runs through everything below: hyssop’s composition is strongly chemotype-dependent — the neurotoxic ketones pinocamphone and isopinocamphone dominate some populations and are nearly absent in others ^{27Reference 27Nurzyńska-Wierdak R · 2026ReviewOntogenetic and Environmental Variability of Hyssop (Hyssopus officinalis L.) Essential Oil Composition and Activity — [review]View study →} — so results tied to one oil batch or one extract type transfer poorly to the dried herb or tea most people actually use.

0. Evidence by indication

Support is an experimental score I’m building — a composite weighted by study type (human > animal > in vitro > review) and study volume. It’s a beta: a fast way to rank strength of evidence at a glance, not a validated metric, and I’ll keep honing the formula over time. Each indication name links down to its write-up.

Indication	Support	Rests on
Respiratory & anti-asthma	███████░░░ 68%	One small human RCT (mixed, subgroup-only) plus three concordant rodent airway-inflammation models; syrup/decoction, not oil.
Antioxidant	██████░░░░ 61%	Several consistent in vitro assays; phenolic-rich extracts, activity rated moderate-to-weak. No human data.
Antidiabetic	██████░░░░ 59%	Isolated α-glucosidase inhibitors + two animal models of postprandial hyperglycaemia; aqueous/alcoholic leaf extract.
Anti-inflammatory	██████░░░░ 56%	One study spanning COX-2 assay, rat paw-oedema and docking; extract, not oil (oil was inactive).
Antimicrobial	█████░░░░░ 52%	Multiple in vitro panels incl. H. pylori; moderate potency, essential-oil-driven, no clinical data.
Antispasmodic	█████░░░░░ 50%	Single ex vivo ileum study + strong traditional carminative use; effect is essential-oil / isopinocamphone.
Gastroprotective	████░░░░░░ 44%	One indomethacin-ulcer rat study; antioxidant/mucus mechanism. Single report.
Anticancer	████░░░░░░ 42%	Cytotoxicity in a few tumour cell lines + one rat glioblastoma model; no selectivity data in humans.
Antiviral	████░░░░░░ 40%	Two historic in vitro anti-HIV reports + one innate-immune (TLR) study; old, unreplicated, cell-based.

1. Respiratory & anti-asthma

The strongest indication, though the human data are thin and mixed. A 2024 randomised, triple-blind, placebo-controlled trial (n=60, mild-to-moderate asthma, hyssop syrup 5 ml twice daily) found that patients with productive cough improved on FEV1, peak expiratory flow, MEF25-75% and wheezing severity — but patients with dry cough got worse on the same indices ^{1Reference 1Daneshfard B et al. · 2024RCTEffect of Hyssop (Hyssopus officinalis) Syrup on Mild to Moderate Asthma — [randomised double-blind placebo-controlled trial]View study →}. The benefit was therefore subgroup-specific, and the authors frame it as a case for syndrome-based patient selection rather than a general asthma treatment. Supporting this, three rodent models of ovalbumin-induced asthma report that aqueous/water extracts of the “Uygur herb” hyssop reduce eosinophilic airway inflammation, normalise serum IgE/IgG, correct the MMP-9/TIMP-1 imbalance driving airway remodelling, and shift GATA-3/STAT-3 versus T-bet expression toward a less Th2-skewed profile ^{2,3,4Reference 2Ma X et al. · 2014AnimalEffect of Hyssopus officinalis L. on inhibiting airway inflammation and immune regulation in a chronic asthmatic mouse model — [mouse model — in vivo]View study →Reference 3Ma X et al. · 2014AnimalThe Effects of Uygur Herb Hyssopus officinalis L. on the Process of Airway Remodeling in Asthmatic Mice — [mouse model — in vivo]View study →Reference 4Wang HY et al. · 2011AnimalThe effect of Uygur medicine Hyssopus officinalis L. on expression of T-bet, GATA-3 and STAT-3 mRNA in lung tissue of asthma rats — [rat model — in vivo]View study →}. The traditional expectorant reputation is consistent with the 1,8-cineole and marrubiin content, but no study isolates an expectorant mechanism in humans.

Gap: a single small RCT with a mixed, subgroup-dependent result; the animal work uses a specific Chinese/Uygur extract, and none of it tests the tea or dried herb at ordinary doses.

2. Antioxidant

Hyssop’s antioxidant activity is its most-replicated in vitro property, driven by phenolic acids and flavonoids rather than the oil. Ethanolic and aqueous extracts scavenge DPPH radicals and show ferric-reducing (FRAP) and Trolox-equivalent capacity, with the activity tracking rosmarinic acid, chlorogenic acid, caffeic acid and free luteolin ^{5,7,8Reference 5Vlase L et al. · 2014In vitroEvaluation of antioxidant and antimicrobial activities and phenolic profile for Hyssopus officinalis, Ocimum basilicum and Teucrium chamaedrys — [in vitro]View study →Reference 7Michalak M et al. · 2024In vitroPhytochemical Profile and Antioxidant and Protective Activities of Various Types of Extracts from Hyssopus officinalis L. and Grindelia robusta Nutt. — [in vitro]View study →Reference 8Fathiazad F et al. · 2011In vitroPhytochemical analysis and antioxidant activity of Hyssopus officinalis L. from Iran — [in vitro]View study →}. However, characterised subsp. aristatus preparations rated the antioxidant capacity only moderate-to-weak (DPPH IC50 56–200 µg/ml), a useful corrective to broad “rich in antioxidants” claims ^{6Reference 6Mićović T et al. · 2021In vitroAntioxidant, Antigenotoxic and Cytotoxic Activity of Essential Oils and Methanol Extracts of Hyssopus officinalis L. subsp. aristatus (Godr.) Nyman (Lamiaceae) — [in vitro]View study →}. The essential oil contributes little; the phenolic fraction does the work.

Gap: purely in vitro, no cellular or human endpoint, and activity is moderate at best — not a standout even among culinary Lamiaceae.

3. Antidiabetic

This is the most mechanistically concrete of hyssop’s metabolic claims. Two α-glucosidase-inhibiting compounds — syringoylglycerol glucosides — were isolated and structurally characterised from dried hyssop leaves ^{11Reference 11Matsuura H et al. · 2004In vitroIsolation of alpha-glucosidase inhibitors from hyssop (Hyssopus officinalis) — [in vitro — constituent isolation]View study →}. Functionally, hyssop extract inhibited sucrose and maltose digestion in the rat everted gut sac and blunted post-load hyperglycaemia in sucrose- and maltose-fed mice (300 and 100 mg/kg), while leaving pure-glucose absorption unaffected — i.e. it slows complex-carbohydrate breakdown rather than glucose uptake ^{12Reference 12Miyazaki H et al. · 2003AnimalInhibitory effects of hyssop (Hyssopus officinalis) extracts on intestinal alpha-glucosidase activity and postprandial hyperglycemia — [animal model — in vivo (rat, mouse)]View study →}. In streptozotocin-diabetic rats, a 500 mg/kg alcoholic extract for one month lowered glucose and modulated GSK-3β, C-fos, NF-κB and cholesterol-transporter (ABCA1/ABCG1) gene expression ^{13Reference 13Abdel-Megeed RM et al. · 2020AnimalHyssopus officinalis exerts hypoglycemic effects on streptozotocin-induced diabetic rats via modulating GSK-3β, C-fos, NF-κB, ABCA1 and ABCG1 gene expression — [rat model — in vivo]View study →}. The signal is coherent (isolated actives → enzyme mechanism → two animal models) but entirely preclinical.

Gap: no human glycaemic data, no dose-finding, and the effect is preparation-specific (methanol/ethanol leaf extracts, not culinary amounts).

4. Anti-inflammatory

A single well-designed study carries this indication across three levels of evidence. Methanol extracts of hyssop herb inhibited COX-2 by 54–63% at 20 µg/ml — statistically indistinguishable from celecoxib — while the essential oil was inactive; the same extracts significantly reduced carrageenan-induced rat paw oedema at 200 mg/kg, and molecular docking attributed the effect to chlorogenic and rosmarinic acid binding COX-2 ^{9Reference 9Mićović T et al. · 2022In vitroIn vitro, in vivo and in silico evaluation of the anti-inflammatory potential of Hyssopus officinalis L. subsp. aristatus (Godr.) Nyman (Lamiaceae) — [in vitro, in vivo (rat) and in silico]View study →}. The COX-2 selectivity (little COX-1 effect) is mechanistically interesting. The airway-inflammation models ^{2,4Reference 2Ma X et al. · 2014AnimalEffect of Hyssopus officinalis L. on inhibiting airway inflammation and immune regulation in a chronic asthmatic mouse model — [mouse model — in vivo]View study →Reference 4Wang HY et al. · 2011AnimalThe effect of Uygur medicine Hyssopus officinalis L. on expression of T-bet, GATA-3 and STAT-3 mRNA in lung tissue of asthma rats — [rat model — in vivo]View study →} point the same direction via cytokine modulation.

Gap: one primary study; no human anti-inflammatory data; the active preparation is the phenolic extract, not the oil or the whole herb.

5. Antimicrobial

Antimicrobial testing is consistent but modest. Ethanolic extracts showed in vitro activity against a bacterial/fungal panel alongside their phenolic profiling ^{5Reference 5Vlase L et al. · 2014In vitroEvaluation of antioxidant and antimicrobial activities and phenolic profile for Hyssopus officinalis, Ocimum basilicum and Teucrium chamaedrys — [in vitro]View study →}, and the essential oil inhibited Helicobacter pylori in an improved broth-microdilution assay ^{10Reference 10Knezevic P et al. · 2018In vitroA colorimetric broth microdilution method for assessment of Helicobacter pylori sensitivity to antimicrobial agents — [in vitro]View study →}. Activity is generally in the moderate range typical of aromatic Lamiaceae oils and is attributed to 1,8-cineole and other oxygenated monoterpenes.

Gap: all in vitro; no clinical antimicrobial use is supported, and potency does not stand out against better-studied oils (thyme, oregano).

6. Antispasmodic

Hyssop’s traditional carminative/antispasmodic reputation has one direct mechanistic study. In isolated guinea-pig ileum, the essential oil and its component isopinocamphone inhibited acetylcholine- and BaCl2-induced contractions concentration-dependently (IC50 ~42 and ~62 µg/ml) and blocked CaCl2-induced contraction, implicating calcium-channel-independent smooth-muscle relaxation; limonene and beta-pinene were inactive ^{14Reference 14Lu M et al. · 2002Muscle relaxing activity of Hyssopus officinalis essential oil on isolated intestinal preparations — [ex vivo (isolated guinea-pig ileum)]View study →}. The effect is real but demonstrated ex vivo and specifically for the essential oil — the same neurotoxic fraction.

Gap: ex vivo only, and the active preparation is the oil, which is not recommended for ingestion; no evidence the tea reproduces this.

7. Gastroprotective

One rodent study supports a gastroprotective effect: an ethanolic leaf extract (250 and 500 mg/kg for 10 days) reduced ulcer index and lipid peroxidation (TBARS) while raising mucus, SOD, GSH and catalase in indomethacin-induced gastric ulcer in rats, with histology confirming mucosal protection ^{15Reference 15Tahir M et al. · 2022AnimalGastroprotective effect of Hyssopus officinalis L. leaves via reduction of oxidative stress in indomethacin-induced gastric ulcer in experimental rats — [rat model — in vivo]View study →}. The mechanism is antioxidant/cytoprotective and dovetails with the carminative-stomachic traditional use.

Gap: a single animal study; no replication and no human data.

8. Anticancer

Cytotoxic activity is documented in cell lines but is preliminary. Methanol extracts reduced viability and induced apoptosis in C6 glioma cells and showed some effect in a rat glioblastoma model ^{19Reference 19Khaksar S et al. · 2022In vitroThe Effects of Methanol Extracts of Hyssopus officinalis on Model of Induced Glioblastoma Multiforme (GBM) in Rats — [in vitro and rat model — in vivo]View study →}; rosmarinic-acid-containing callus extracts were antiproliferative against MCF-7 breast-cancer cells ^{20Reference 20Yahia Darwish H et al. · 2020In vitroInduction of Biosynthetic Genes Related to Rosmarinic Acid in Plant Callus Culture and Antiproliferative Activity Against Breast Cancer Cell Line — [in vitro (cell line)]View study →}; and characterised oils/extracts were cytotoxic to SW480, MDA-MB-231 and HeLa lines in the antioxidant study ^{6Reference 6Mićović T et al. · 2021In vitroAntioxidant, Antigenotoxic and Cytotoxic Activity of Essential Oils and Methanol Extracts of Hyssopus officinalis L. subsp. aristatus (Godr.) Nyman (Lamiaceae) — [in vitro]View study →}. None of this establishes tumour-selective toxicity or in vivo efficacy at tolerable doses.

Gap: cell-line-dominated with one rat model; no selectivity, pharmacokinetic or human data — a generic cytotoxicity signal, not an anticancer therapy.

9. Antiviral

The antiviral story is historically notable but unreplicated. In 1990, crude leaf extracts inhibited HIV-1 replication in vitro (syncytia formation, reverse transcriptase, p17/p24) without toxicity to uninfected cells ^{16Reference 16Kreis W et al. · 1990In vitroInhibition of HIV replication by Hyssop officinalis extracts — [in vitro]View study →}, and in 1995 a polysaccharide (MAR-10) isolated from the aqueous extract showed concentration-dependent anti-HIV-1 activity with broad anti-glycosidase action ^{17Reference 17Gollapudi S et al. · 1995In vitroIsolation of a previously unidentified polysaccharide (MAR-10) from Hyssop officinalis that exhibits strong activity against human immunodeficiency virus type 1 — [in vitro]View study →}. A more recent study found that hyssop extract activated endosomal Toll-like receptors (TLR3/7/8/9) and MyD88/NF-κB signalling in human PBMCs, suggesting an innate-antiviral immune mechanism ^{18Reference 18Ghasempour M et al. · 2022In vitroThe impact of Hyssop (Hyssopus officinalis) extract on activation of endosomal toll-like receptors and their downstream signaling pathways — [in vitro (human PBMC)]View study →}. Caffeic acid and tannins are the usual candidate antivirals.

Gap: the direct anti-HIV work is 30+ years old, in vitro, and never advanced; the TLR study is a single cell-based report. No clinical antiviral evidence.

Mechanisms

Mechanism	Drives	Key compounds
GABAergic modulation / neuronal excitability (convulsant); smooth-muscle Ca²⁺-independent relaxation	antispasmodic; essential-oil neurotoxicity	pinocamphone, isopinocamphone
mucoactive/expectorant; antimicrobial membrane disruption	respiratory, antimicrobial	1,8-cineole
bitter secretomotor / expectorant	respiratory, digestive	marrubiin
radical scavenging, COX-2 inhibition, antiviral	antioxidant, anti-inflammatory, antiviral, anticancer	rosmarinic acid, chlorogenic acid, caffeic acid
radical scavenging, NF-κB / cytokine modulation	antioxidant, anti-inflammatory	luteolin, diosmin, apigenin
intestinal α-glucosidase inhibition	antidiabetic	syringoylglycerol glucosides

Clinical trials

No registered clinical trials for Hyssopus officinalis were identified on ClinicalTrials.gov; the sole human study is one published asthma-syrup RCT (n=60), and everything else is preclinical.

Completed	Planned	Terminated	Preclinical
1 (published RCT, unregistered)	0	0	~80

Last checked: July 2026.

Safety

Hyssop leaf, used as a culinary herb or a mild tea, has a long record of safe use, and no serious adverse effects are reported at those amounts. The concentrated essential oil is neurotoxic: its monoterpene ketones pinocamphone and isopinocamphone are potent central convulsants, and both human poisonings and controlled animal studies confirm dose-dependent tonic-clonic seizures from ingested hyssop oil — the oil is more convulsant than sage oil, with convulsions in rats above ~0.13 g/kg ^{21,22,23Reference 21Millet Y et al. · 1979AnimalExperimental study of the toxic convulsant properties of commercial preparations of essences of sage and hyssop — [animal model — experimental (rat)]View study →Reference 22Millet Y et al. · 1981Case reportToxicity of some essential plant oilsView study →Reference 23Burkhard PR et al. · 1999Case reportPlant-induced seizures: reappearance of an old problem — [case reports]View study →}. This is a hazard of the oil, not the water infusion: the tea carries only a fraction of these ketones. Because they act on the GABAergic system, the oil and high doses of the herb must be avoided by anyone with epilepsy or a seizure disorder, in pregnancy, and in young children ^{25Reference 25Bahr TA et al. · 2019Systematic reviewThe Effects of Various Essential Oils on Epilepsy and Acute Seizure: A Systematic Review — [systematic review]View study →}.

A further concern applies specifically to the oil: some hyssop chemotypes contain substantial methyleugenol (reported up to ~28% of the oil), a compound the EMA classes as a genotoxic carcinogen, so internal use of the essential oil is not advised ^{6Reference 6Mićović T et al. · 2021In vitroAntioxidant, Antigenotoxic and Cytotoxic Activity of Essential Oils and Methanol Extracts of Hyssopus officinalis L. subsp. aristatus (Godr.) Nyman (Lamiaceae) — [in vitro]View study →}. Composition varies enormously by chemotype and origin — some French populations contain little pinocamphone — so oil safety cannot be assumed from the species name alone ^{27Reference 27Nurzyńska-Wierdak R · 2026ReviewOntogenetic and Environmental Variability of Hyssop (Hyssopus officinalis L.) Essential Oil Composition and Activity — [review]View study →}. Note also that Hyssopus officinalis is distinct from the unrelated Agastache “anise/giant hyssop”; the safety picture here applies to true hyssop. Rare Lamiaceae-family allergic cross-reactivity has been documented within the mint family ^{26Reference 26Benito M et al. · 1996Case reportLabiatae allergy: systemic reactions due to ingestion of oregano and thyme — [case reports]View study →}.

Only a mechanistic in vitro study exists for interactions: the oil’s pinanone ketones (cis-/trans-3-pinanone) are metabolised by human CYP3A4 ^{24Reference 24Höld KM et al. · 2002In vitroMetabolism and mode of action of cis- and trans-3-pinanones (the active ingredients of hyssop oil) — [in vitro — mechanistic (liver microsomes, CYP3A4)]View study →}, but no clinical drug–herb interaction has been studied — treat the interaction profile as not clinically assessed. Hyssop has no adopted EU/EMA-HMPC herbal monograph and is not official in the major pharmacopoeias, so there is no authoritative efficacy-and-safety assessment behind it.

Pregnancy & lactation

Avoid. No dedicated reproductive-toxicity study of hyssop was found, so this is a precautionary verdict — grounded in the essential oil’s convulsant/neurotoxic ketones, the herb’s traditional emmenagogue/abortifacient reputation, and the possible methyleugenol content, rather than on a formal assessment. Avoid the essential oil and high herb doses in pregnancy and while breastfeeding; culinary amounts of the leaf are traditionally regarded as acceptable but have not been formally evaluated.

References

1. Daneshfard B, et al. (2024). Effect of Hyssop (Hyssopus officinalis) Syrup on Mild to Moderate Asthma — [randomised double-blind placebo-controlled trial]. Tanaffos. https://pubmed.ncbi.nlm.nih.gov/39959798/
2. Ma X, et al. (2014). Effect of Hyssopus officinalis L. on inhibiting airway inflammation and immune regulation in a chronic asthmatic mouse model — [mouse model — in vivo]. Exp Ther Med. https://pubmed.ncbi.nlm.nih.gov/25289025/
3. Ma X, et al. (2014). The Effects of Uygur Herb Hyssopus officinalis L. on the Process of Airway Remodeling in Asthmatic Mice — [mouse model — in vivo]. Evid Based Complement Alternat Med. https://pubmed.ncbi.nlm.nih.gov/25383084/
4. Wang HY, et al. (2011). The effect of Uygur medicine Hyssopus officinalis L. on expression of T-bet, GATA-3 and STAT-3 mRNA in lung tissue of asthma rats — [rat model — in vivo]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. https://pubmed.ncbi.nlm.nih.gov/21806885/
5. Vlase L, et al. (2014). Evaluation of antioxidant and antimicrobial activities and phenolic profile for Hyssopus officinalis, Ocimum basilicum and Teucrium chamaedrys — [in vitro]. Molecules. https://pubmed.ncbi.nlm.nih.gov/24786688/
6. Mićović T, et al. (2021). Antioxidant, Antigenotoxic and Cytotoxic Activity of Essential Oils and Methanol Extracts of Hyssopus officinalis L. subsp. aristatus (Godr.) Nyman (Lamiaceae) — [in vitro]. Plants (Basel). https://pubmed.ncbi.nlm.nih.gov/33916934/
7. Michalak M, et al. (2024). Phytochemical Profile and Antioxidant and Protective Activities of Various Types of Extracts from Hyssopus officinalis L. and Grindelia robusta Nutt. — [in vitro]. Curr Top Med Chem. https://pubmed.ncbi.nlm.nih.gov/39253917/
8. Fathiazad F, et al. (2011). Phytochemical analysis and antioxidant activity of Hyssopus officinalis L. from Iran — [in vitro]. Adv Pharm Bull. https://pubmed.ncbi.nlm.nih.gov/24312758/
9. Mićović T, et al. (2022). In vitro, in vivo and in silico evaluation of the anti-inflammatory potential of Hyssopus officinalis L. subsp. aristatus (Godr.) Nyman (Lamiaceae) — [in vitro, in vivo (rat) and in silico]. J Ethnopharmacol. https://pubmed.ncbi.nlm.nih.gov/35358622/
10. Knezevic P, et al. (2018). A colorimetric broth microdilution method for assessment of Helicobacter pylori sensitivity to antimicrobial agents — [in vitro]. J Pharm Biomed Anal. https://pubmed.ncbi.nlm.nih.gov/29448222/
11. Matsuura H, et al. (2004). Isolation of alpha-glucosidase inhibitors from hyssop (Hyssopus officinalis) — [in vitro — constituent isolation]. Phytochemistry. https://pubmed.ncbi.nlm.nih.gov/14697274/
12. Miyazaki H, et al. (2003). Inhibitory effects of hyssop (Hyssopus officinalis) extracts on intestinal alpha-glucosidase activity and postprandial hyperglycemia — [animal model — in vivo (rat, mouse)]. J Nutr Sci Vitaminol (Tokyo). https://pubmed.ncbi.nlm.nih.gov/14703310/
13. Abdel-Megeed RM, et al. (2020). Hyssopus officinalis exerts hypoglycemic effects on streptozotocin-induced diabetic rats via modulating GSK-3β, C-fos, NF-κB, ABCA1 and ABCG1 gene expression — [rat model — in vivo]. J Diabetes Metab Disord. https://pubmed.ncbi.nlm.nih.gov/32550200/
14. Lu M, et al. (2002). Muscle relaxing activity of Hyssopus officinalis essential oil on isolated intestinal preparations — [ex vivo (isolated guinea-pig ileum)]. Planta Med. https://pubmed.ncbi.nlm.nih.gov/11914956/
15. Tahir M, et al. (2022). Gastroprotective effect of Hyssopus officinalis L. leaves via reduction of oxidative stress in indomethacin-induced gastric ulcer in experimental rats — [rat model — in vivo]. Drug Chem Toxicol. https://pubmed.ncbi.nlm.nih.gov/31694395/
16. Kreis W, et al. (1990). Inhibition of HIV replication by Hyssop officinalis extracts — [in vitro]. Antiviral Res. https://pubmed.ncbi.nlm.nih.gov/1708226/
17. Gollapudi S, et al. (1995). Isolation of a previously unidentified polysaccharide (MAR-10) from Hyssop officinalis that exhibits strong activity against human immunodeficiency virus type 1 — [in vitro]. Biochem Biophys Res Commun. https://pubmed.ncbi.nlm.nih.gov/7741735/
18. Ghasempour M, et al. (2022). The impact of Hyssop (Hyssopus officinalis) extract on activation of endosomal toll-like receptors and their downstream signaling pathways — [in vitro (human PBMC)]. BMC Res Notes. https://pubmed.ncbi.nlm.nih.gov/36503515/
19. Khaksar S, et al. (2022). The Effects of Methanol Extracts of Hyssopus officinalis on Model of Induced Glioblastoma Multiforme (GBM) in Rats — [in vitro and rat model — in vivo]. J Mol Neurosci. https://pubmed.ncbi.nlm.nih.gov/35963984/
20. Yahia Darwish H, et al. (2020). Induction of Biosynthetic Genes Related to Rosmarinic Acid in Plant Callus Culture and Antiproliferative Activity Against Breast Cancer Cell Line — [in vitro (cell line)]. Pak J Biol Sci. https://pubmed.ncbi.nlm.nih.gov/32700853/
21. Millet Y, et al. (1979). Experimental study of the toxic convulsant properties of commercial preparations of essences of sage and hyssop — [animal model — experimental (rat)]. Rev Electroencephalogr Neurophysiol Clin. https://pubmed.ncbi.nlm.nih.gov/493616/
22. Millet Y, et al. (1981). Toxicity of some essential plant oils. Clinical and experimental study — [case reports and animal experimental study]. Clin Toxicol. https://pubmed.ncbi.nlm.nih.gov/7333081/
23. Burkhard PR, et al. (1999). Plant-induced seizures: reappearance of an old problem — [case reports]. J Neurol. https://pubmed.ncbi.nlm.nih.gov/10460442/
24. Höld KM, et al. (2002). Metabolism and mode of action of cis- and trans-3-pinanones (the active ingredients of hyssop oil) — [in vitro — mechanistic (liver microsomes, CYP3A4)]. Xenobiotica. https://pubmed.ncbi.nlm.nih.gov/12028660/
25. Bahr TA, et al. (2019). The Effects of Various Essential Oils on Epilepsy and Acute Seizure: A Systematic Review — [systematic review]. Evid Based Complement Alternat Med. https://pubmed.ncbi.nlm.nih.gov/31239862/
26. Benito M, et al. (1996). Labiatae allergy: systemic reactions due to ingestion of oregano and thyme — [case reports]. Ann Allergy Asthma Immunol. https://pubmed.ncbi.nlm.nih.gov/8630713/
27. Nurzyńska-Wierdak R (2026). Ontogenetic and Environmental Variability of Hyssop (Hyssopus officinalis L.) Essential Oil Composition and Activity — [review]. Plants (Basel). https://pubmed.ncbi.nlm.nih.gov/41681651/